Suppression of pokeweed mitogen-driven human IgM and IgG responses by the hydroxylamine of sulfamethoxazole

被引:12
作者
Sisson, ME
Rieder, MJ [1 ]
Bird, IA
Almawi, WY
机构
[1] Univ Western Ontario, Div Clin Pharmacol, London, ON N6C 2V5, Canada
[2] Univ Western Ontario, Dept Paediat, London, ON N6C 2V5, Canada
[3] Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6C 2V5, Canada
[4] Univ Western Ontario, JP Robarts Child Hlth Res Inst, London, ON N6C 2V5, Canada
[5] Univ Western Ontario, Childrens Hosp Western Ontario, London, ON N6C 2V5, Canada
[6] Amer Univ Beirut, Dept Biochem, Beirut, Lebanon
[7] Univ Western Ontario, Dept Med, London, ON N6C 2V5, Canada
来源
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 1997年 / 19卷 / 05期
基金
英国医学研究理事会;
关键词
sulfonamides; IgG; IgM; adverse drug reactions;
D O I
10.1016/S0192-0561(97)00027-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine the effect(s) of reactive sulfonamide metabolites on antibody production by human lymphocytes. Methods: Human peripheral blood cells (PBMCs) were isolated from control volunteers and incubated with the hydroxylamine of sulfamethoxazole (SMX H/A), a reactive metabolite of the most commonly used sulfonamide, in increasing concentrations. PBMCs were then stimulated to produce antibody with pokeweed mitogen. After incubation for 8 days, concentrations of IgG and IgM were determined in supernatant using an ELISA assay. Results: Production of both IgG and IgM was significantly suppressed by sub-lethal concentrations of SMX H/A in a concentration-dependent fashion (p<0.05). Suppression was more marked for IgM production (maximal decline to 80% of baseline antibody production) than For IgG production (maximal decline to 57% of baseline antibody production). No suppresion was seen when cells were incubated with sulfamethoxazole in concentrations up to 400 mu M. This suppression was not related to changes in cell viability; at a concentration of 25 mu M of SMX H/A, IgM and IgG concentration were reduced by 47 +/- 8.7% and 73 +/- 7.2%, while cell viability (percentage of live cells) was 93 +/- 5%. Suppression was time-dependent, increasing over the incubation periods to reach a plateau after 2 h of incubation. Conclusion: Sulfonamide reactive metabolites, in concentrations which are achieved during therapy, suppress antibody production by PWM-stimulated human cells. This may explain, in part, the alterations in immunity associated with hypersensitivity reactions to the sulfonamides. This may also have implications for patients receiving sulfonamide therapy and concurrent immunosuppressive therapy. (C) 1997 International Society for Immunopharmacology.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 22 条
[1]   SULFAMETHOXAZOLE IS METABOLIZED TO THE HYDROXYLAMINE IN HUMANS [J].
CRIBB, AE ;
SPIELBERG, SP .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (05) :522-526
[2]  
CRIBB AE, 1990, DRUG METAB DISPOS, V18, P784
[3]   SUCCESSFUL INTERMITTENT CHEMOPROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONITIS [J].
HUGHES, WT ;
RIVERA, GK ;
SCHELL, MJ ;
THORNTON, D ;
LOTT, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (26) :1627-1632
[4]   COMPARISON OF PENTAMIDINE ISETHIONATE AND TRIMETHOPRIM-SULFAMETHOXAZOLE IN TREATMENT OF PNEUMOCYSTIS-CARINII PNEUMONIA [J].
HUGHES, WT ;
FELDMAN, S ;
CHAUDHARY, SC ;
OSSI, MJ ;
COX, F ;
SANYAL, SK .
JOURNAL OF PEDIATRICS, 1978, 92 (02) :285-291
[5]   DRUG-INDUCED SKIN-DISEASE [J].
KAPLAN, AP .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1984, 74 (04) :573-579
[6]   ALTERED PATTERNS OF DRUG-METABOLISM IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
LEE, BL ;
WONG, D ;
BENOWITZ, NL ;
SULLAM, PM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (05) :529-535
[7]  
LEEDER JS, 1991, BIOCHEM PHARMACOL, V41, P575
[8]   ORAL-THERAPY FOR PNEUMOCYSTIS-CARINII PNEUMONIA IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - A CONTROLLED TRIAL OF TRIMETHOPRIM SULFAMETHOXAZOLE VERSUS TRIMETHOPRIM DAPSONE [J].
MEDINA, I ;
MILLS, J ;
LEOUNG, G ;
HOPEWELL, PC ;
LEE, B ;
MODIN, G ;
BENOWITZ, N ;
WOFSY, CB .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (12) :776-782
[9]   DRUG-PROTEIN CONJUGATION AND ITS IMMUNOLOGICAL CONSEQUENCES [J].
PARK, BK ;
KITTERINGHAM, NR .
DRUG METABOLISM REVIEWS, 1990, 22 (01) :87-144
[10]  
PARK BK, 1987, BIOCHEM PHARMACOL, V36, P581